Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Lion Biotechnologies Raises USD100 Million in Financing 12
Partnerships 14
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14
Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18
Lion Biotech Enters into Research Agreement with MedImmune 19
Lion Biotech Enters into Agreement with WuXi AppTec 20
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21
Merger 22
Genesis Biopharma And Lion Biotech Merge 22
Licensing Agreements 23
Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25
Equity Offering 26
Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26
Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27
Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29
Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31
Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32
Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34
Lion Biotech Completes Private Placement Of Units For US$23.3 Million 36
Genesis Biopharma Completes Private Placement Of Shares For US$1.1 Million 38
Iovance Biotherapeutics Inc – Key Competitors 39
Iovance Biotherapeutics Inc – Key Employees 40
Iovance Biotherapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 06, 2018: Iovance Biotherapeutics reports third quarter 2018 financial results and provides corporate update 42
Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update 45
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 47
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 49
Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results 51
Aug 01, 2017: Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results 54
May 01, 2017: Lion Biotechnologies Reports First Quarter 2017 Financial Results 56
Mar 07, 2017: Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 58
Corporate Communications 60
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors 60
Aug 08, 2017: Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer 61
May 25, 2017: Lion Biotechnologies Announces Departure of Chief Financial Officer 62
Product Approvals 63
Aug 31, 2017: Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma 63
Clinical Trials 64
Jun 07, 2018: Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma 64
Jan 24, 2018: Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers 65
Nov 09, 2017: Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting 66
Nov 09, 2017: Iovance Biotherapeutics Announces Presentation on Its cancer Drug candidate LN-145 at SITC Meeting 68
Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-144) at 2017 SITC Annual Meeting 69
Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-145) at 2017 SITC Annual Meeting 70
Sep 13, 2017: Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer 71
Aug 16, 2017: Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer 72
Jun 05, 2017: Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial 73
Jun 01, 2017: Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer 74
May 19, 2017: Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma 75
May 17, 2017: Lion Biotechnologies to Present New Data from Ongoing LN-144 Phase 2 Clinical Trial at 2017 American Society of Clinical Oncology Annual Meeting 76
Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer 77
Other Significant Developments 78
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 78
Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 79
Jun 27, 2017: Lion Biotechnologies Changes Name to Iovance Biotherapeutics 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lion Biotechnologies Raises USD100 Million in Financing 12
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14
Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18
Lion Biotech Enters into Research Agreement with MedImmune 19
Lion Biotech Enters into Agreement with WuXi AppTec 20
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21
Genesis Biopharma And Lion Biotech Merge 22
Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25
Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26
Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27
Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29
Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31
Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32
Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34
Lion Biotech Completes Private Placement Of Units For US$23.3 Million 36
Genesis Biopharma Completes Private Placement Of Shares For US$1.1 Million 38
Iovance Biotherapeutics Inc, Key Competitors 39
Iovance Biotherapeutics Inc, Key Employees 40
Iovance Biotherapeutics Inc, Other Locations 41
Iovance Biotherapeutics Inc, Subsidiaries 41
List of Figures
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9